Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective — Pierre Lévy (2019) | RDL Network
Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France.Objectives: To evaluate monthly p...
Pierre Lévy, Pierre Lévy, David M. Smadja, David M. Smadja, J Dorey, J Dorey, Mondher Toumi, Mondher Toumi, Anna‐Katharina Meinecke, Anna‐Katharina Meinecke, Kevin Bowrin, Kevin Bowrin, J Brière, J Brière
Jan Steffel, Rónán Collins, Matthias Antz, Pieter Cornu, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán, Nigel Rowell, Peter Sinnaeve, Thomas Vanassche, Tatjana Potpara, A. John Camm, Hein Heidbüchel, Professor Gregory Lip, Thomas Deneke, Nikolaos Dagres, Giuseppe Boriani, Tze-Fan Chao, Eue-Keun Choi, Mellanie True Hills, Itamar S Santos, Deirdre A. Lane, Dan Atar, Boyoung Joung, Oana Maria Cole, Mark Field
Daniele Pastori, Professor Gregory Lip, Alessio Farcomeni, Francesco Del Sole, Angela Sciacqua, Francesco Perticone, Rossella Marcucci, Elisa Grifoni, Pasquale Pignatelli, Francesco Violi, Mirella Saliola, Marco Casciaro, Danilo Menichelli, Francesco Cribari, Alberto Paladino, Rony Gingis, Marta Novo, Vittoria Cammisotto, Cristina Nocella, Simona Bartimoccia, Roberto Carnevale,
Professor Gregory Lip, Allison Keshishian, A Kang, X Luo, Nipun Atreja, Y Zhang, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Steven Deitelzweig
Discussion(0)
No comments yet. Be the first to comment.